A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US
Graham, Christopher N., Christodoulopoulou, Alexandra, Knox, Hediyyih N., Sabatelli, Lorenzo, Hechmati, Guy, Garawin, Tamer, Strickler, John H.Language:
english
Journal:
Journal of Medical Economics
DOI:
10.1080/13696998.2018.1510409
Date:
August, 2018
File:
PDF, 977 KB
english, 2018